文献速递药物不良反应与药物警戒

印度药物警戒:现状与未来挑战

Pharmacovigilance in India: Present Scenario and Future Challenges.
PubMed 文献 · Drug Saf · 2019-01-01

印度药物警戒始于1986年,2010年更名为印度药物警戒计划(PvPI),全国已设250个药物不良反应监测中心并开展医护人员培训。PvPI现为WHO合作中心,但在仿制药、生物类似药、特定疾病药物不良反应监测及意识提升等方面仍面临挑战。

要点

  • 印度药物警戒体系由PvPI统筹,全国设250个监测中心并培训医护人员。
  • PvPI已建成WHO合作中心,负责公共卫生项目与监管服务中的药物警戒。
  • 仿制药、生物类似药及特定疾病药物不良反应监测是当前主要挑战。

核心结论

  • 印度药物警戒体系取得显著进展,但仿制药、生物类似药及特定疾病药物不良反应监测等挑战仍存。

研究设计与样本

  • 本文为综述,梳理印度药物警戒体系从1986年ADR监测系统至PvPI的发展历程与现状。

主要发现

  • 印度1998年加入WHO国际药物监测计划未成功,2005年启动国家药物警戒计划,2010年更名为PvPI。
  • 国家协调中心从新德里迁至加济阿巴德的印度药典委员会(IPC)。
  • 全国已建立250个PvPI药物不良反应监测中心,并对医护人员开展培训。
  • IPC-PvPI已成为WHO公共卫生项目与监管服务药物警戒合作中心。

临床怎么用

  • 临床应通过PvPI监测中心上报药物不良反应,促进患者安全与合理用药。
  • 需关注仿制药、生物类似药及降糖、心血管、抗精神病药物的疾病特异性不良反应监测。

局限性

  • 本文为现状综述,未报告具体监测数据、发生率或评估指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pharmacovigilance in India was initiated way back in 1986 with a formal adverse drug reaction (ADR) monitoring system, under supervision of the drug controller of India. India joined the World Health Organization (WHO) Programme for International Drug Monitoring in 1998, but was not successful. Later, the National Programme of Pharmacovigilance was launched in 2005, and was renamed as the Pharmacovigilance Programme of India (PvPI) in 2010. In consideration of having a robust pharmacovigilance system in India, steps were taken. The National Coordination Centre was shifted from New Delhi to the Indian Pharmacopoeia Commission (IPC) in Ghaziabad. The PvPI works to safeguard the health of the Indian population by ensuring that the benefit of medicines outweighs the risks associated with their use. The culture of reporting of ADRs has achieved remarkable success, with 250 PvPI-established adverse drug monitoring centres all over India and provision of training to healthcare professionals. The programme is striving hard to build trust between the physician and the patient, thereby increasing patient safety and the confidence of people in the country's health system, in addition to the detection of substandard medicines and prescribing, dispensing and administration errors. The IPC-PvPI has now become a WHO Collaborating Centre for Pharmacovigilance in Public Health Programmes and Regulatory Services. In spite of these achievements, several challenges are faced by the PvPI, like the monitoring of generic drugs, biosimilars, and disease-specific ADRs of antidiabetic, cardiovascular and antipsychotic drugs and, above all, creating awareness, which is a continual process. At the same time, the PvPI is trying to address other challenges like counterfeit drugs, antimicrobial resistance, and surveillance during mass vaccinations and other national programmes.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Kalaiselvan V, Srivastava S, Singh A, et al. Pharmacovigilance in India: Present Scenario and Future Challenges. Drug Saf. 2019. PMID: 30269244. doi:10.1007/s40264-018-0730-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。